<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00932412</url>
  </required_header>
  <id_info>
    <org_study_id>2006.456/50</org_study_id>
    <nct_id>NCT00932412</nct_id>
  </id_info>
  <brief_title>The CLARA Study From the Acute Leukemia French Association (ALFA 0702 Trial)</brief_title>
  <acronym>CLARA</acronym>
  <official_title>A Randomized Phase II Study of Clofarabine / Intermediate-Dose Cytarabine (CLARA)Versus High-Dose Cytarabine (HDAC) as Consolidation in Younger Patients With Newly-Diagnosed Acute Myeloid Leukemia (AML).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a phase II randomized multicenter study. Patients will be enrolled at time of
      diagnosis and will receive one or two cycles of induction chemotherapy. Patients, without
      indication of intensification by allogeneic stem cell transplantation and/or without HLA
      (Human Leukocyte Antigen)-compatible donor, who attain a CR after one or two cycles of
      induction chemotherapy, will be eligible for the study Clofarabine / Intermediate-Dose
      Cytarabine (CLARA)versus High-Dose Cytarabine (HDAC)and will be randomized between 3 courses
      of CLARA chemotherapy and 3 courses of HDAC chemotherapy as consolidation.

      We will compare efficacy and toxicity among the two arms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Because of the results of our former trial (ALFA-9802) [Thomas, 2005], chemotherapy will be
      combined in each arm with G-CSF (Granulocyte Colony-Stimulating Factor) given during each
      sequence of chemotherapy in order to increase the blast priming.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DFS (disease free survival) following first remission achievement (CR : Complete Remission or CRp : Complete Remission but platelet count &lt; 100 x109/L) in younger patients with intermediate-risk or unfavorable-risk AML.</measure>
    <time_frame>2 years</time_frame>
    <description>As all these patients are eligible for allogenic stem cell transplantation in first remission if they have a donor and the comparison of interest primarily concerns non-transplanted patients, it is planned: 1) to exclude patients with an identified donor; 2) to adjust Relapse Free survival (RFS) comparison on the interaction with stem cell transplantation in first remission; and 3) to censure at transplant time the patients allografted before disease progression after randomization (late donor identification) as sensitivity analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>• Safety profile of CLARA versus HDAC consolidation courses</measure>
    <time_frame>2 years</time_frame>
    <description>All toxicity encountered during therapy will be evaluated according to the CTC expanded Common Toxicity Criteria and causal relationship to investigational products will be reported.
Serious Adverse Events encountered 3 MONTHS after the last cycle of study chemotherapy (induction/salvage/CLARA/HDAC), whether or not ascribed to the study, will be recorded in the Serious Adverse Event form.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Possible predictors to response</measure>
    <time_frame>2 years</time_frame>
    <description>Possible predictors to response: with respect to cytogenetics risk groups and mutational status: FLT3 (Fms-like tyrosine kinase 3), MLL (myeloid/ lymphoid or mixed-lineage leukemia), CEBPA (CCAAT / enhancer binding protein α) and NPM(Nucleophosmin))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• MRD (Minimal Residual Disease) level</measure>
    <time_frame>2 years</time_frame>
    <description>Evaluation of MRD in patients with AML in clinical remission is a potentially useful tool for assessing the risk of relapse and guiding further therapeutic decisions. Once an aberrant pattern is identified at diagnosis, it will serve as a &quot;patient-specific probe&quot; to be used, with standard triple/quadruple labelling, to track residual disease longitudinally. Bone marrow and peripheral blood samples for MRD evaluation will be collected at fixed time points:
End of induction in patients achieving CR/CRp.
End of consolidation 3.
Every 6 months during follow-up for 2 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Overall cumulative incidence of relapse</measure>
    <time_frame>120 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Overall survival (OS)</measure>
    <time_frame>2 years</time_frame>
    <description>OS will be defined as the time from diagnosis to death or last contact with the patient</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">735</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>CLARA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clofarabine / Intermediate-Dose Cytarabine (CLARA) with G-CSF given during each sequence of chemotherapy in order to increase the blast priming.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HDAC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>High-Dose Cytarabine (HDAC) with G-CSF given during each sequence of chemotherapy in order to increase the blast priming.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CLARA</intervention_name>
    <description>Clofarabine 30 mg/m2/day IV (2h) on days 2 to 6 (administered as a 2h infusion in 250 ml of 0.9% normal saline solution) Cytarabine 1 g/m2/day intravenous (2h) 4 hours later on days 1 to 5 (administered as a 2h infusion in 250 ml of 5% dextrose in water) G-CSF 5 microg/kg/day intravenous from day 1 to day 6 (administered as a 30 mn infusion in 20 ml of dextrose 5% in water)</description>
    <arm_group_label>CLARA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HDAc</intervention_name>
    <description>Cytarabine 3 g/m2/12h intravenous (3h) on days 1, 3, 5 (administered as a 3h infusion in 250 ml of 5% dextrose in water) G-CSF 5 microg/kg/day intravenous from day 1 to day 5 (administered as a 30 mn infusion in 20 ml of dextrose 5% in water)</description>
    <arm_group_label>HDAC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria at registration:

          1. Age 18 years or more and less than 60 years

          2. With:

             A morphologically proven diagnosis of AML according to the WHO classification,
             cytogenetically (standard karyotype, FISH-MLL) and molecularly (FLT3, CEBPA, NMP1)
             defined.

          3. ECOG (Eastern Cooperative Oncology Group) performance status 0 to 2.

          4. Have adequate renal and hepatic function as indicated by the following laboratory
             values:

               -  Creatinine clearance (calculated by the cockcroft and Gault method) ≥ 40mL/min;

               -  AST (Aspartate amino transférase) and ALT (Alanine Amino Transférase ) &lt; or =
                  2.5N; total bilirubin &lt; or = 2N (unless related to the underlying disease).

          5. Cardiac function determined by radionuclide or echography within normal limits.

          6. Women of child-bearing potential (i.e. women who are pre-menopausal or not surgically
             sterile) must use acceptable contraceptive methods, and must have a negative serum or
             urine pregnancy test within 2 weeks prior the beginning treatment on this trial.

          7. Must be able and willing to give written informed consent.

          8. The subject must be covered by a social security system.

        Exclusion Criteria at registration:

          1. Patients with AML with favorable risk cytogenetics: M3-AML; CBF-AML including t(8:21),
             inv(16), or t(16;16) AML.

          2. Ph-positive AML.

          3. AML following diagnosed myeloproliferation or patient with prior history of MDS known
             for more than 3 months

          4. Prior treatment with chemotherapy or radiotherapy for another tumor.

          5. Prior tumor, if not stable for at least two years, except in-situ carcinoma and skin
             carcinoma

          6. Compromised organ function judged to be lifethreatening by the Investigator.

          7. Positive serology for HIV (Human Immunodeficiency Virus), HBV (Hepatitis B Virus) and
             HBC (Hepatitis C Virus)(except post vaccination)

          8. Uncontrolled active infection of any kind or bleeding. Patients with infections who
             are under active treatment with antibiotics and whose infections are controlled may be
             entered to the study.

          9. Other active malignancy.

         10. Patients concurrently receiving any other standard or investigational treatment for
             their leukemia, with the exception of hydroxyurea.

        INCLUSION CRITERIA AT RANDOMIZATION

          1. Patients with either in first CR/CRp after the first induction course or in first
             CR/CRp after salvage therapy.

          2. ECOG performance status 0 to 2.

          3. AST and ALT &lt; or = 2.5N; total bilirubin &lt; or = 2N.

          4. Creatinine clearance ≥40mL/min (calculated by the cockcroft and Gault method or by
             MDRD (see http://nephron.org/cgi-bin/MDRD_GFR/cgi)

          5. Patient without HLA identical donor.

             EXCLUSION CRITERIA AT RANDOMIZATION

          6. Patients belonging to the intermediate 1 risk group (CEBPA+ or NPM1+ without Flt3-ITD)
             in CR/CRp after the first induction course. These patients will go out of the study
             and receive consolidation cycles based on HD-AraC (Aracytine).

          7. Known central nervous system involvement with AML.

          8. Uncontrolled active infection of any kind or bleeding.

          9. Compromized organ function judged to be lifethreatening by the Investigator.

         10. Patient with HLA identical donor identified.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xavier THOMAS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Sud - CHU Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Regional et Universitaire d'Angers</name>
      <address>
        <city>Angers</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Victor Dupouy</name>
      <address>
        <city>Argenteuil</city>
        <zip>95107</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Avicenne - bobigny</name>
      <address>
        <city>Bobigny</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Boulogne/Mer</name>
      <address>
        <city>Boulogne / Mer</city>
        <zip>62280</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Clemenceau - chu Caen</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier René Dubos</name>
      <address>
        <city>Cergy Pontoise</city>
        <zip>95303</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HIA Percy</name>
      <address>
        <city>Clamart</city>
        <zip>92141</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de Corbeil</name>
      <address>
        <city>Corbeil</city>
        <zip>91100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Dubocage</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Dunkerque</name>
      <address>
        <city>Dunkerque</city>
        <zip>59395</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Michallon</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Versailles</name>
      <address>
        <city>Le Chesnay</city>
        <zip>78150</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Schaffner</name>
      <address>
        <city>Lens</city>
        <zip>62307</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Dupuytren</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli-Calmette</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Meaux</name>
      <address>
        <city>Meaux</city>
        <zip>77104</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU - Hôtel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre A. Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Archet 1</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital St Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pitié-Salpetrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paris Necker</name>
      <address>
        <city>Paris</city>
        <zip>75743</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Haut Lévêque</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon - Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre-benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital V. Provo</name>
      <address>
        <city>Roubaix</city>
        <zip>59056</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel - CHRU ROUEN</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Huguenin</name>
      <address>
        <city>Saint Cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Valenciennes</name>
      <address>
        <city>Valenciennes</city>
        <zip>59322</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Brabois</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2009</study_first_submitted>
  <study_first_submitted_qc>July 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 3, 2009</study_first_posted>
  <last_update_submitted>September 20, 2016</last_update_submitted>
  <last_update_submitted_qc>September 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Younger Patients with Newly-Diagnosed Acute Myeloid Leukemia (AML).</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Clofarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

